Time course of erythrocyte antioxidant activity in patients treated by thrombolysis for acute myocardial infarction.
The deleterious effects of free radicals in acute myocardial ischaemia/reperfusion are rather well known. However, the possibility that thrombolysis positively affects the recovery of blood antioxidant capacity in the later postinfarction period, and thus contributes to the better overall outcome of these patients, has not yet been investigated. We followed the time course of erythrocyte antioxidant activity in 45 patients with first acute myocardial infarction (AMI), who were treated with streptokinase. Success of thrombolysis was evaluated by noninvasive clinical signs of reperfusion using continuous vector cardiography. The patients were divided into two groups according to successful or unsuccessful, reperfusion, The control group consisted of 24 healthy subjects. Glutathione peroxidase (GPX) and superoxide dismutase (SOD) were determined immediately after admittance to the hospital (0 hours) and after subsequent thrombolytic therapy (1.5, 6, 12, and 24 hours after initiation of infusion of streptokinase), and 2, 4, and 8 days after AMI. Patients with AMI had decreased antioxidant enzyme activity at the time of admit- tance to the hospital, showing that the oxidative/antioxidative balance is disturbed early during the ischemic phase of AMI. In AMI patients without successful reperfusion, erythrocyte antioxidant enzyme activity remains low during the postinfarction period of 7 days. It can be concluded that prolonged ischemia reduces antioxidant enzyme activity. AMI patients with successful reperfusion have a significant rise in the activity of antioxidant enzymes within the first hours after thrombolysis, followed by a decrease until the third postinfarction day. During the subsequent postinfarction period, erythrocyte antioxidant activity gradually recovered and reached control levels. These beneficial effects of reperfusion on erythrocyte antioxidant status might contribute to the better overall prognosis of these patients.
Simić
Dragan
D
Institute of Cardiovascular Diseases, Clinical Center of Serbia, Belgrade, Serbia and Montenegro.
Mimić-Oka
Jasmina
J
Pljesa
Marija
M
Milanović
Dragan
D
Radojević
Savić
S
Ivanović
Branislava
B
Kalimanovska-Ostrić
Dimitra
D
Matić
Danica
D
Simić
Tatjana
T
D000975:Antioxidants / Q000378:metabolism*; D004912:Erythrocytes / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D015425:Myocardial Reperfusion; D018384:Oxidative Stress; D011379:Prognosis; D013300:Streptokinase / Q000627:therapeutic use; D013318:Stroke Volume; D013482:Superoxide Dismutase / Q000378:metabolism; D015912:Thrombolytic Therapy; D016277:Ventricular Function, Left / Q000502:physiology
D000975:Antioxidants; D005343:Fibrinolytic Agents; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D013300:Streptokinase